Argentine study confirms Sputnik V highly effective against Manaus variant of coronavirus

RIO DE JANEIRO, BRAZIL – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces that a study carried out by Argentina’s Institute of Virology of the National University of Cordoba and the Government of Cordoba has confirmed the neutralization effectiveness of the Russian two-dose Sputnik V coronavirus vaccine against the Manaus (Brazilian) variant and overall strong immune response after vaccination with Sputnik V.

The study specifically confirmed that the immunity generated thanks to vaccination with Sputnik V neutralizes the Manaus (Brazilian) variant in those who received one dose as well as subjects inoculated with two doses of the vaccine.

The study also demonstrated that:

99.65% of subjects induced IgG antibodies to COVID-19 on 42nd day after receiving the 2nd dose; and 85.5% of subjects induced IgG antibodies to COVID-19 on 14th day after receiving the 1st dose.

To date the Russian vaccine has been registered in 66 countries with total population of over 3.2 billion people. Post-vaccination studies in a number of countries demonstrate that Sputnik V is the safest and most effective vaccine against coronavirus. Sputnik V ranks second among coronavirus vaccines globally in terms of the number of approvals issued by government regulators.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error